Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

Next Previous
Trial Profile

A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elenbecestat (Primary)
  • Indications Alzheimer's disease; Dementia; Mild cognitive impairment
  • Focus Adverse reactions
  • Sponsors Eisai Inc

    • Most Recent Events

    • 02 Dec 2019 According to an Eisai Inc media release, results from this trial will be presented at 12th Clinical Trials on Alzheimers Disease (CTAD) conference taking place in San Diego, California in the United States, from December 4 to 7, 2019.
    • 13 Sep 2019 Status changed from active, no longer recruiting to discontinued, according to an Eisai Co Ltd media release.
    • 13 Sep 2019 According to an Eisai Co Ltd media release, this trial has been discontinued by Eisai and Biogen as a consequence of the discontinuation of MISSION AD1 and MISSION AD2 trials. The MISSION trials have been discontinued as per the recommendation of the Data Safety Monitoring Board (DSMB) due to unfavorable risk-benefit ratio.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top